Anti-RBD scFv (CB6)-Fc mRNA-LNP

Item Information
Catalog #

The spike protein of COVID-19 is a glycoprotein that helps the virus attach to various surfaces in the built environment, increasing the potential for virus transmission. The best-known vaccines we use are the spike protein vaccines delivered via mRNA. While the role of vaccination in controlling outbreaks is undeniable, the recurring emergence of new variants of Covid-19, such as the Delta and Omicron variants, poses new challenges, particularly their rapid global spread. Within the spike protein, there is a receptor-binding domain, considered a key viral element that allows the coronavirus to dock with target cells. Mutations in the RBD appear in new variants, such as the Delta variant with 2 mutations and the Omicron variant with 15 mutations, posing challenges for pandemic vaccination. Studies have revealed that a large number of antibodies show neutralization activity by targeting the RBD of COVID-19 viruses. The CB6, a human monoclonal antibody obtained from a patient convalescing from COVID-19 has been identified to target the RBD of SARS-CoV-2 with an ability to neutralize the pandemic viruses.
This product is designed as a tool for the delivery and expression of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-RBD (CB6) scFv/CD3 mutant Fc in this product is approximately 70 kD and consists of anti-RBD (CB6) scFv (single-chain variable fragment), mutant human Fc and CD3ze signaling domains. The full-length amino acid sequence of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA-LNP product is available upon request.

Product Overview
mRNA-LNPs suspended in PBS (-Ca, -Mg) (pH: 7.0-7.4).
Cell Type Tested
Application & Handing
Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container. It is important not to spin for too long as this may rupture mRNA-LNPs. Do not vortex. Work with mRNA-LNPs on ice and minimize the time that the product spends at room temperature. After handling the product during experiments, return immediately to ice. mRNA-LNP products should only be handled with certified RNase-free reagents and consumables. Use of filtered pipette tips is highly recommended.
4°C; ice
For Research Use Only. Not for use in diagnostic procedures.